Product Details for NDA 021272
REMODULIN (TREPROSTINIL)
1MG/ML
Marketing Status: Prescription
2.5MG/ML
Marketing Status: Prescription
5MG/ML
Marketing Status: Prescription
10MG/ML
Marketing Status: Prescription
20MG/ML
Marketing Status: Prescription
1MG/ML
Marketing Status: Prescription
Active Ingredient: TREPROSTINIL
Proprietary Name: REMODULIN
Dosage Form; Route of Administration: INJECTABLE; IV (INFUSION), SUBCUTANEOUS
Strength: 1MG/ML
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: AP
Application Number: N021272
Product Number: 001
Approval Date: May 21, 2002
Applicant Holder Full Name: UNITED THERAPEUTICS CORP
Marketing Status: Prescription
Patent and Exclusivity Information
REMODULIN (TREPROSTINIL)
Proprietary Name: REMODULIN
Dosage Form; Route of Administration: INJECTABLE; IV (INFUSION), SUBCUTANEOUS
Strength: 1MG/ML
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: AP
Application Number: N021272
Product Number: 001
Approval Date: May 21, 2002
Applicant Holder Full Name: UNITED THERAPEUTICS CORP
Marketing Status: Prescription
Patent and Exclusivity Information
2.5MG/ML
Marketing Status: Prescription
Active Ingredient: TREPROSTINIL
Proprietary Name: REMODULIN
Dosage Form; Route of Administration: INJECTABLE; IV (INFUSION), SUBCUTANEOUS
Strength: 2.5MG/ML
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: AP
Application Number: N021272
Product Number: 002
Approval Date: May 21, 2002
Applicant Holder Full Name: UNITED THERAPEUTICS CORP
Marketing Status: Prescription
Patent and Exclusivity Information
REMODULIN (TREPROSTINIL)
Proprietary Name: REMODULIN
Dosage Form; Route of Administration: INJECTABLE; IV (INFUSION), SUBCUTANEOUS
Strength: 2.5MG/ML
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: AP
Application Number: N021272
Product Number: 002
Approval Date: May 21, 2002
Applicant Holder Full Name: UNITED THERAPEUTICS CORP
Marketing Status: Prescription
Patent and Exclusivity Information
5MG/ML
Marketing Status: Prescription
Active Ingredient: TREPROSTINIL
Proprietary Name: REMODULIN
Dosage Form; Route of Administration: INJECTABLE; IV (INFUSION), SUBCUTANEOUS
Strength: 5MG/ML
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: AP
Application Number: N021272
Product Number: 003
Approval Date: May 21, 2002
Applicant Holder Full Name: UNITED THERAPEUTICS CORP
Marketing Status: Prescription
Patent and Exclusivity Information
REMODULIN (TREPROSTINIL)
Proprietary Name: REMODULIN
Dosage Form; Route of Administration: INJECTABLE; IV (INFUSION), SUBCUTANEOUS
Strength: 5MG/ML
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: AP
Application Number: N021272
Product Number: 003
Approval Date: May 21, 2002
Applicant Holder Full Name: UNITED THERAPEUTICS CORP
Marketing Status: Prescription
Patent and Exclusivity Information
10MG/ML
Marketing Status: Prescription
Active Ingredient: TREPROSTINIL
Proprietary Name: REMODULIN
Dosage Form; Route of Administration: INJECTABLE; IV (INFUSION), SUBCUTANEOUS
Strength: 10MG/ML
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: AP
Application Number: N021272
Product Number: 004
Approval Date: May 21, 2002
Applicant Holder Full Name: UNITED THERAPEUTICS CORP
Marketing Status: Prescription
Patent and Exclusivity Information
REMODULIN (TREPROSTINIL)
Proprietary Name: REMODULIN
Dosage Form; Route of Administration: INJECTABLE; IV (INFUSION), SUBCUTANEOUS
Strength: 10MG/ML
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: AP
Application Number: N021272
Product Number: 004
Approval Date: May 21, 2002
Applicant Holder Full Name: UNITED THERAPEUTICS CORP
Marketing Status: Prescription
Patent and Exclusivity Information
20MG/ML
Marketing Status: Prescription
Active Ingredient: TREPROSTINIL
Proprietary Name: REMODULIN
Dosage Form; Route of Administration: INJECTABLE; IV (INFUSION), SUBCUTANEOUS
Strength: 20MG/ML
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code:
Application Number: N021272
Product Number: 005
Approval Date: Jul 30, 2021
Applicant Holder Full Name: UNITED THERAPEUTICS CORP
Marketing Status: Prescription
Patent and Exclusivity Information
Proprietary Name: REMODULIN
Dosage Form; Route of Administration: INJECTABLE; IV (INFUSION), SUBCUTANEOUS
Strength: 20MG/ML
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code:
Application Number: N021272
Product Number: 005
Approval Date: Jul 30, 2021
Applicant Holder Full Name: UNITED THERAPEUTICS CORP
Marketing Status: Prescription
Patent and Exclusivity Information